Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220376 · ClinicalTrials.gov registry record · Phase 3
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
A Phase 3 study of Overactive Bladder Syndrome, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00220376 is a Phase 3 study of Overactive Bladder Syndrome that has completed, run by Pfizer. The trial reports 1 study location across 1 state.
The verdict
NCT00220376, a Phase 3 study of Overactive Bladder Syndrome, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome. Subjects completing the 12 week treatment period of SP584 had the opportunity to participate if eligibility was confirmed. They received fesoterodine 8mg with the option to reduce the dose to 4mg during scheduled visits, and to increase again to 8mg, a procedure which can be followed on an annual basis. The primary variables are long-term safety and tolerability, measured by observation and assessment of adverse events and duration on therapy. Further safety variables include the assessment of laboratory parameters, changes in ECG, physical exams and measurement of residual urine. Secondary efficacy variables included various parameters derived from micturition diaries and the evaluation of Quality of Life questionnaires
Conditions Studied
Interventions
- DRUG SPM 907
Study Locations (1)
North Carolina
- Schwarz - RTP
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220376
The ClinicalTrials.gov registry entry for NCT00220376 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 1 intervention - of which SPM 907 is the first listed.
NCT00220376 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00220376 about?
NCT00220376 is a clinical study titled "Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome". This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome. Subjects completing the 12 week treatment period of SP584 had the opportunity to participate if eligibility was confirmed. They received ...
What is the current status of trial NCT00220376?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-04. Estimated completion is 2007-07.
What conditions does trial NCT00220376 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome.
What interventions are being tested in trial NCT00220376?
The interventions under investigation include: SPM 907 (DRUG).
Who is sponsoring clinical trial NCT00220376?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00220376 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxybutynin for Post-surgical Bladder Pain and Urgency
RECRUITING · Phase 3
-
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
COMPLETED · Phase 3
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.